Sculptor Capital’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Sculptor Capital’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-8,600	Closed	-$40K	–	1449
2021 Q4	$40K	Hold	8,600	–	–	﹤0.01%	1088
2021 Q3	$66K	Buy	+8,600	New	+$72.9K	﹤0.01%	895
2021 Q1	–	Sell	-134,900	Closed	-$921K	–	840
2020 Q4	$921K	Sell	134,900 -3,300	-2%	-$26.5K	﹤0.01%	358
2020 Q3	$1.54M	Buy	138,200 +32,500	+31%	+$297K	0.01%	250
2020 Q2	$664K	Buy	+105,700	New	+$405K	0.01%	217
2018 Q3	–	Sell	-152,700	Closed	-$1.1M	–	319
2018 Q2	$1.1M	Buy	+152,700	New	+$1.04M	0.01%	193

Other funds holding SRNE

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Sculptor Capital's SRNE Position: Q1 2022 in Review

Sculptor Capital sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2022, closing a stake of 8,600 shares — an estimated $40K sold.

Sculptor Capital first reported a position in SRNE in Q2 2018 and held it in 7 quarters. The position peaked at $1.54M in Q3 2020. 235 funds tracked by Wall St. Rank hold SRNE as of Q1 2022.

Sculptor Capital reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2022 after selling out during the quarter.
Sculptor Capital sold 8,600 Sorrento Therapeutics, Inc. shares in Q1 2022, an estimated $40K.
Sculptor Capital first reported a position in Sorrento Therapeutics, Inc. in Q2 2018 and held it in 7 quarters.
Sculptor Capital's Sorrento Therapeutics, Inc. position peaked at $1.54M in Q3 2020.
235 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2022.

Based on Sculptor Capital's 13F filing for Q1 2022, filed 13 May 2022.